Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications.

Company profile
Ticker
LCI
Exchange
Website
CEO
Timothy Crew
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
NETHERLANDS SECURITIES INC
SEC CIK
Corporate docs
Subsidiaries
Cody Laboratories, Inc. • Silarx Pharmaceuticals, Inc. • Kremers Urban Pharmaceuticals, Inc. ...
IRS number
230787699
LCI stock data
Latest filings (excl ownership)
8-K
Material Modifications to Rights of Security Holders
7 Feb 23
10-Q
2023 Q2
Quarterly report
2 Feb 23
8-K
Lannett Reports Improved Fiscal 2023 Second Quarter Financial Results; Raises Full-year Guidance
2 Feb 23
8-K
Submission of Matters to a Vote of Security Holders
26 Jan 23
8-K
Cost Associated with Exit or Disposal Activities
16 Dec 22
DEF 14A
Definitive proxy
29 Nov 22
8-K
Entry into a Material Definitive Agreement
14 Nov 22
PRE 14A
Preliminary proxy
10 Nov 22
10-Q
2023 Q1
Quarterly report
3 Nov 22
8-K
Lannett Reports Better Than Expected Financial Results
3 Nov 22
Transcripts
LCI
Earnings call transcript
2023 Q2
1 Feb 23
LCI
Earnings call transcript
2023 Q1
2 Nov 22
LCI
Earnings call transcript
2022 Q4
25 Aug 22
LCI
Earnings call transcript
2022 Q3
5 May 22
LCI
Earnings call transcript
2022 Q2
4 Feb 22
LCI
Earnings call transcript
2022 Q1
4 Nov 21
LCI
Earnings call transcript
2021 Q4
26 Aug 21
LCI
Earnings call transcript
2021 Q3
6 May 21
LCI
Earnings call transcript
2021 Q2
4 Feb 21
LCI
Earnings call transcript
2021 Q1
4 Nov 20
Latest ownership filings
Financial summary
Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 22 | Jun 21 | Jun 20 | Jun 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 60.85 mm | 60.85 mm | 60.85 mm | 60.85 mm | 60.85 mm | 60.85 mm |
Cash burn (monthly) | 7.36 mm | 3.57 mm | 12.09 mm | 16.11 mm | 6.41 mm | 4.29 mm |
Cash used (since last report) | 22.20 mm | 10.76 mm | 36.50 mm | 48.64 mm | 19.34 mm | 12.96 mm |
Cash remaining | 38.65 mm | 50.09 mm | 24.35 mm | 12.21 mm | 41.51 mm | 47.89 mm |
Runway (months of cash) | 5.3 | 14.0 | 2.0 | 0.8 | 6.5 | 11.2 |
Institutional ownership, Q3 2022
46.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 58 |
Opened positions | 1 |
Closed positions | 13 |
Increased positions | 2 |
Reduced positions | 20 |
13F shares | Current |
---|---|
Total value | 30.35 mm |
Total shares | 20.06 mm |
Total puts | 77.60 k |
Total calls | 61.00 k |
Total put/call ratio | 1.3 |
Largest owners | Shares | Value |
---|---|---|
Telemus Capital | 7.38 mm | $3.39 mm |
Renaissance Technologies | 2.04 mm | $916.00 k |
D. E. Shaw & Co | 1.89 mm | $12.30 mm |
D. E. Shaw & Co. | 1.50 mm | $674.00 k |
MintBroker International | 1.40 mm | $7.21 mm |
Vanguard | 740.88 k | $333.00 k |
LSV Asset Management | 711.75 k | $320.00 k |
BLK Blackrock | 574.42 k | $258.00 k |
Staley Capital Advisers | 515.15 k | $232.00 k |
IVZ Invesco | 390.73 k | $176.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
17 Nov 22 | John C Chapman | Common Stock | Buy | Acquire P | No | No | 0.51 | 20,000 | 10.20 k | 174,324 |
10 Nov 22 | Crew Timothy C | Common Stock | Buy | Acquire P | No | Yes | 0.48 | 15,000 | 7.20 k | 604,291 |
10 Nov 22 | Lepore Patrick G | Common Stock | Buy | Acquire P | No | No | 0.49 | 100,000 | 49.00 k | 587,145 |
14 Sep 22 | Melissa Rewolinski | Common stock | Buy | Acquire P | No | No | 0.49 | 31,159 | 15.27 k | 93,259 |
7 Sep 22 | Abt John | Common Stock | Payment of exercise | Dispose F | No | No | 0.47 | 950 | 446.50 | 118,825 |
News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
15 Mar 23
Why Jounce Therapeutics Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket
15 Mar 23
12 Health Care Stocks Moving In Tuesday's After-Market Session
14 Mar 23
10 Short Squeeze Candidates: Getty Images, Genius Brands, Lannett And More
27 Feb 23
10 Short Squeeze Candidates To Watch This Week: Getty, Lannett, AirSculpt And More
13 Feb 23
Press releases
LANNETT REPORTS IMPROVED FISCAL 2023 SECOND QUARTER FINANCIAL RESULTS; RAISES FULL-YEAR GUIDANCE
1 Feb 23
LANNETT ANNOUNCES 1 FOR 4 REVERSE STOCK SPLIT
25 Jan 23
LANNETT TO REPORT FISCAL 2023 SECOND-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, FEBRUARY 1
25 Jan 23
LANNETT PROVIDES DEVELOPMENT UPDATE ON BIOSIMILAR INSULIN PRODUCTS
4 Jan 23